VinpocetineBanned Substance

• Start with the awkward part: vinpocetine is not actually banned in the US.
  
  FDA's position is a tentative conclusion published in 2016, and no final rule has followed it [1]. ^[1]

• FDA's September 6, 2016 Federal Register notice, Docket FDA-2016-N-2523, made two separate arguments [2].
  
  The first: vinpocetine is not a vitamin, mineral, amino acid, or botanical, so it fails the legal definition of a dietary ingredient [2]. ^[2]

• The second rests on the drug-first exclusion in section 201(ff)(3)(B) of the Federal Food, Drug, and Cosmetic Act [2].
  
  Vinpocetine was authorized as an investigational new drug in 1981, with Phase 3 trials published 1985-1988, years before the first supplement notification in 1997 [2]. ^[2]

• What sharpened FDA's attention was a 2015 analysis led by Pieter Cohen of Harvard Medical School, with colleagues at the University of Mississippi [5].
  
  They bought 23 vinpocetine supplements from two major US retail chains, and most carried inaccurate label information about the vinpocetine inside [5]. ^[5]

• Other regulators went further than FDA has. Australia, New Zealand, and Canada bar vinpocetine from their supplement markets outright [18]. ^[18]

• In the EU including Germany, plus Russia and China, it moves only through prescription channels under brand names such as Cavinton [5].
  
  The US Department of Defense also lists it on its Prohibited Dietary Supplement Ingredients List for service members [19]. ^[5]

• A disagreement worth naming, not smoothing over. Consumer and trade press routinely describe vinpocetine as banned in the US, while FDA's proceeding sits unfinished and the product stays on shelves [1].
  
  The outright bans belong to Australia, New Zealand, and Canada; the EU, Russia, and China route it through prescriptions instead [18]. ^[1]

• Reproductive harm is the headline hazard here. FDA's June 3, 2019 safety communication advises pregnant women, and women who could become pregnant, not to take vinpocetine [1]. ^[1]

• That warning rests on a National Toxicology Program prenatal developmental study in Sprague Dawley rats [4].
  
  At the highest dose tested, 60 mg/kg body weight per day, post-implantation loss reached 83.13%, against 3.29% in vehicle controls [4]. ^[4]

• Whole-litter resorption hit 12 of 20 pregnant rats in that group [4].
  
  Ventricular septal heart defects and skeletal anomalies showed up at the lower 20 mg/kg/day dose as well [4]. ^[4]

• Sources disagree on what the rat data means for people. FDA and NTP note that blood levels in the study animals resembled human levels after a single supplement dose [1].
  
  A dietary-supplement regulatory consultant quoted in trade press countered that the rats got roughly 1,000 times a typical human dose, calling FDA "a bit out over the skis" [21].
  
  That is a government risk assessment against industry-aligned commentary, and this page is not resolving it for you. ^[1]

• Outside pregnancy, reported effects at supplement and therapeutic doses include stomach pain, nausea, insomnia, pressure-type headache, dizziness, jitteriness, facial flushing, dry mouth, and drowsiness [8].
  
  Transient drops in blood pressure and rises in heart rate are also on record [8]. ^[8]

• Two case reports stand out.
  
  A 73-year-old man developed agranulocytosis, a sharp fall in white blood cells, after 50 days of vinpocetine, and it resolved once he stopped [7]. ^[7]

• The second describes a fixed drug eruption with rapid heartbeat and stomach pain in a man taking a combined Ginkgo biloba and vinpocetine product [8].
  
  Which ingredient was responsible is unknown, so read it as a signal about combination products rather than about vinpocetine alone [8]. ^[8]

• Bleeding risk is the interaction to watch. Vinpocetine appears to slow blood clotting, raising bruising and bleeding risk alongside aspirin, clopidogrel, warfarin, heparin, and NSAIDs [11].
  
  It may also prolong warfarin's effect and add to the action of blood-pressure-lowering drugs [11]. ^[11]

• In vitro work suggests vinpocetine strongly inhibits P-glycoprotein, the transporter governing how many other drugs move through the body [11].
  
  The clinical significance is not established — a laboratory finding so far, not a documented human interaction [11]. ^[11]

• Contraindications commonly listed: hypersensitivity to vinpocetine or other vinca alkaloids, incomplete hemostasis after a cerebral hemorrhage, pregnancy and breastfeeding, and anyone under 18 [9]. ^[9]

• 1981: FDA authorizes vinpocetine for investigation as a new drug [2].
  
  1985-1988: Phase 3 clinical trials are conducted and reported in the published literature [2]. ^[2]

• 1997: the first New Dietary Ingredient notification is filed and acknowledged without objection [2].
  
  Four more vinpocetine NDI notifications follow over later years, none of them drawing formal action [2]. ^[2]

• 2013: NTP's National Institute of Environmental Health Sciences publishes a Federal Register request for information on vinpocetine's exposure, pharmacokinetics, and toxicity [22].
  
  Its stated reason: published safety data were very limited for something already sold widely [22]. ^[22]

• 2015: the Cohen label-accuracy study lands [5].
  
  Senator Claire McCaskill, then the top Democrat on the Senate Special Committee on Aging, urges FDA to suspend sales and asks 10 retailers to pull the products voluntarily [5]. ^[5]

• September 6-7, 2016: FDA publishes its Federal Register notice under Docket FDA-2016-N-2523 [2].
  
  The 60-day public comment period closed on November 7, 2016 [1]. ^[2]

• June 3, 2019: FDA issues its warning to pregnant women and women who could become pregnant, citing NTP's rat and rabbit findings [1].
  
  It also asked supplement firms to add a matching warning to product labeling [1]. ^[1]

• As of FDA's most recent page update: still no final rule [1].
  
  The agency continues to call its 2016 conclusion tentative, so US sales carry on while Australia, New Zealand, and Canada have already shut the door [1]. ^[1]

• One note on the dates above: they line up across FDA, the Federal Register, and NTP primary documents [2].
  
  No conflicting dates surfaced in this research pass, so nothing in this timeline is disputed. ^[2]

No human lethal or toxic dose for vinpocetine appears in the sources reviewed, and no case report of acute human poisoning was found either [4].

Every quantitative figure below comes from animal developmental studies rather than from people.

In NTP's rat dose range-finding work, pregnant rats received 0, 20, 40, 80, 160, or 320 mg/kg body weight per day by gavage [4].

At 80 mg/kg/day and above, dams lost entire litters to resorption, with one exception in the 160 mg/kg group [4].

The definitive study used 0, 5, 20, or 60 mg/kg/day, and heart and skeletal defects appeared even at 20 mg/kg/day [4].

Rabbits were less sensitive. Embryo-fetal survival was affected only at 300 mg/kg/day, with nothing at 150 mg/kg/day or below [4].

Human use sits far lower, at roughly 5-30 mg per dose up to three times daily, or about 15-45 mg/day in clinical studies [10].

For a 60-70 kg adult that works out to roughly 0.07-0.9 mg/kg/day, orders of magnitude under the rat doses [10].

Self-reported nootropic use reaches single 60 mg doses, and pharmacokinetic modeling puts that peak blood level about 10 times higher than 5 mg three times daily [10].

None of this establishes a human toxic threshold.

One clinical study gave Alzheimer's patients 60 mg/day for a year with no significant harmful effects reported, under monitoring rather than in an overdose [8]. ^[4]

No vinpocetine-specific poison-control protocol or antidote turned up in the sources reviewed [14].

The general US guidance applies instead: call Poison Help at 1-800-222-1222, or use the free webPOISONCONTROL online triage tool [14].

Call 911 rather than the hotline if the person collapses, seizes, has trouble breathing, or cannot be woken [14].

What a real call can look like: the Tennessee Poison Center described an adult woman on atorvastatin and escitalopram who took Addium, a multi-ingredient nootropic containing vinpocetine [13].

Her facial and limb flushing resolved within 2 hours, with no medical intervention [13].

For wider context, US poison centers field a dietary-supplement exposure call about every 24 minutes [15].

Children under 6 account for 70% of those calls, 97.3% happen at home by swallowing, and about 4.5% end in a serious medical outcome [15].

Energy products and botanicals such as yohimbe drive most of those serious outcomes, not vinpocetine [15].

No source quantifies vinpocetine's own share of these calls, and none offers dedicated overdose management guidance. ^[14]